New drug combo tested to fight tough breast cancer
NCT ID NCT03542175
Summary
This study tested the safety of adding an oral drug called rucaparib to the standard radiation therapy given after surgery. It involved 31 women with a hard-to-treat type of breast cancer that had not fully disappeared after initial chemotherapy. The main goal was to find a safe dose of the drug to use alongside radiation, not to cure the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Bergen
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Commack
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Westchester
Harrison, New York, 10604, United States
-
Memorial Sloan Kettering at Basking Ridge
Basking Ridge, New Jersey, 07920, United States
-
Norwalk Hospital
Norwalk, Connecticut, 06850, United States
Conditions
Explore the condition pages connected to this study.